As shown in Figure 2B, the TACE+TKIs+PD-1 treatment had better OS than the TACE+TKIs treatment in patients with HBV infection(HR=0.435;95% CI:0.258-0.731;P=0.002), tumor size ≤ 5cm(HR=0.375;95% CI:0.144-0.973;P=044), BCLC stage B(HR=0.538;95% CI:0.313-0.924;P=0.025), absence of portal invasion(HR=0.414;95% CI:0.208-0.824;P=0.012), cirrhosis(HR=0.437;95% CI:0.263-0.728;P=0.001), with AFP level ≤200(HR=0.420;95% CI:0.211-0.835;P=0.013), Child-Pugh class A (HR=0.317,95% CI:0.167-0.601;P<0.001), and ECOG 0(HR=0.180,95% CI:0.058-0.560;P=0.003). This evidence concerns the gene AFP and Cirrhosis.